Brokerage firm Jefferies Upgrades its rating on GlaxoSmithKline plc (ADR)(NYSE:GSK). The shares have been rated Buy. Previously, the analysts had a Hold rating on the shares. The rating by Jefferies was issued on Jul 14, 2016.
GlaxoSmithKline plc (ADR) (GSK) made into the market gainers list on Mondays trading session with the shares advancing 0.71% or 0.31 points. Due to strong positive momentum, the stock ended at $44.23, which is also near the day’s high of $44.3101. The stock began the session at $43.98 and the volume stood at 33,52,803 shares. The 52-week high of the shares is $45.49 and the 52 week low is $37.24. The company has a current market capitalization of $107,711 M and it has 2,43,52,50,000 shares in outstanding.
GlaxoSmithKline plc (ADR)(GSK) last announced its earnings results on Apr 27, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $8.91B. Analysts had an estimated revenue of $8.45B. Earnings per share were $0.28. Analysts had estimated an EPS of $0.29.
GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSK’s Vaccines has a portfolio of over 30 paediatric adolescent adult travel vaccines. GSK’s Established Products Portfolio includes over 50 off-patent products as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories such as wellness oral health nutrition and skin health. Its brands include Sensodyne Panadol Horlicks Polident Paradontax Tums ENO NiQuitin/Nicorette Abreva Zovirax and Aquafresh. It operates in the United Kingdom the United States Belgium and China.